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cA Reassessment of Needs and Practice Patterns in Pharmacologic
Prophylaxis of Venous Thromboembolism Following Elective Major
Surgery
Quadan M, Polk HC Jr, Hohmann SF, et al. Ann Surg 2011;253:215-20.
Conclusion: Physician judgment is important in determining suscep-
tibility to venous thromboembolism (VTE) in patients after major abdom-
inal surgery.
Summary: There were an estimated 900,000 cases of VTE in hospi-
talized patients, in the U.S. in 2005, with 300,000 fatal (Heit JA, et al.
American Society of Hematology Annual Meeting Abstract 2005;106 ab-
stract 910). However, pulmonary embolism (PE) after major elective ab-
dominal surgery seems very uncommon. Opponents of a “one size fits all”
approach to VTE prophylaxis believe routine VTE prophylaxis increases cost
and compromises staff and facility resources to administer what is potentially
dangerous treatment for an infrequent event in certain categories of patients.
Trials of VTE prophylaxis use some VTE events as end points for efficacy,
such as calf vein thrombosis, that may not be clinically significant at least in
the short-term. In 2004, the Kentucky Surgical Care Improvement Project
found a very low rate of PE in 5285 elective specialty surgery patients: 15
PEs were detected in these patients, and none were fatal, despite erratic and
very limited use of VTE prophylaxis. The authors queried the University
Health System Consortium database from 2004 and also found a very low
rate of VTE complication in patients undergoing elective operations (Surg
2008;144:654-60). It is possible, however, that American College of Chest
Physicians (ACCP) recommendations may have altered practices of VTE
prophylaxis in elective surgical patients, and rates of fatal and nonfatal PE
could be influenced by changing indications for VTE prophylaxis. The
authors’ study was designed to assess and compare rates of VTE prophylaxis
and PE from an 18-month consecutive period in 2003 to 2004 to an
identical period of observation in 2007 to 2008. Their hope was to assess the
effect of the ACCP recommendations advocating an increase in VTE pro-
phylaxis.
The authors queried the University Health System Consortium data-
base comprising data from 123 academic teaching hospitals. They identified
patients undergoing colorectal resections, total hip replacement, total knee
replacement, and hysterectomies from two 18-consecutive month periods:
2003 to 2004 and 2007 to 2008. VTE rates ranged from 0.6% to 3.2% and
PE rates ranged from 0.28% to 1.09%. Use of VTE prophylaxis increased for
all procedures between 2003 to 2004 and 2007 to 2008, except for
hysterectomy. Comparing the two periods, the authors found VTE rates
were not significantly affected among patients who received pharmacologic
prophylaxis and actually decreased in patients who did not receive any
pharmacologic prophylaxis, despite an absence of significant change of
severity of illness in the patient populations.
Comment: The author’s arguments appear to be a step backward from
routine VTE prophylaxis to an approach where “the need for prophylaxis
would be assessed on an individual basis, based on retrospective data, expert
consensus, and clinical judgment.” What the authors have actually found is
that in a practice where VTE prophylaxis is encouraged and withheld only
for specific reasons, the rate of VTE complications, specifically fatal PE, is
low. It does not follow that the same results can be obtained with the
approach of withholding VTE prophylaxis unless one judges it to be specif-
ically required in individual cases.
Influence of Preceding Length of Anticoagulant Treatment and Initial
Presentation of Venous Thromboembolism on Risk of Recurrence
After Stopping Treatment: Analysis of Individual Participants’ Data
From Seven Trials
Boutitie F, Pinede L, Schulman S. BMJ 2011;342:d3036; doi:10.1136/
bmj.d3036.
Conclusion: Risk of recurrent venous thromboembolism (VTE) after
3 months of anticoagulation therapy is similar to longer courses of antico-
agulation. A higher risk of recurrence is present when the initial VTE event
is a proximal deep venous thrombosis (DVT) or pulmonary embolism (PE).
Summary: Randomized data indicate that at least 3 months of antico-
agulation is preferable to shorter periods to reduce recurrent VTE after an
initial VTE episode. Studies evaluating the optimal length of vitamin K
antagonist treatment after VTE have compared two lengths of treatment.
When only two lengths of treatment are compared, it is not possible to tell if
the superior length of treatment from one individual study is the overall
optimal length of treatment. The authors pooled data from seven individual
comparative trials using a spectrum of lengths of treatment for VTE. The
primary goal was to identify the shortest treatment length that most reduces
v
p
1220he risk of recurrent VTE after stopping treatment with vitamin a K antag-
nist. They also sought to determine the optimal length of anticoagulant
reatment with respect to specific subgroups at time of presentation VTE
proximal or distal DVT or PE) and whether thrombus recurrence was
nfluenced by a temporary risk factor or whether the VTE was unprovoked.
he seven studies comprised 2925 men and women with a first-time VTE
vent who did not have cancer. The primary end point was the first recurrent
enous VTE event after stopping anticoagulation during up to 24 months of
ollow-up. The pooled data indicated recurrence was lower after isolated
istal DVT then after proximal DVT (HR, 0.49; 95% CI, 0.34-0.71).
ecurrence was similar after PE and proximal DVT (HR, 1.19; 95% CI,
.87-1.63). Recurrence was lower after a VTE event associated with a
emporary risk factor than after an unprovoked VTE (HR, 0.55; 95% CI,
.41-0.74). Recurrence was similar if treatment was stopped at 3 months
ompared with 6 months or later (HR 1.19; 95% CI, 0.86-1.65). Recur-
ence was higher if anticoagulation was stopped at 1 or 1.5 months com-
ared with 3 months or later (HR, 1.52; 95% CI, 1.14-2.02). Overall, higher
ates of recurrence were associated with shorter durations of anticoagulation
nd were confined to the first 6 months after stopping vitamin K antagonist
herapy.
Comment: The analysis indicates patients with a VTE event who do
ot have an obvious indication for indefinite anticoagulation can stop
itamin K antagonist treatment after 3 months. Among the limitations of
his study were that D-dimer levels and vascular laboratory assessment of the
tatus of the venous thrombus at the end of anticoagulation were not
ncluded as potential variables influencing duration of anticoagulation.
erhaps patients with unprovoked VTE will, in the future, be better stratified
y additional variables to determine which patients will have a low risk of
ecurrence with only 3 months of treatment.
ilostazol Versus Aspirin for Secondary Prevention of Vascular Events
fter Stoke of Arterial Origin
amal AK, Naqvi I, Husain MR, et al. Stroke 2011;42:e382-4.
Conclusion: In Asian populations after an initial stroke, cilostazol is
uperior to aspirin in secondary prevention of stroke, myocardial infarction,
r vascular death.
Summary: This is a summary of a Cochrane Review. The review is
ased on the fact that aspirin for secondary prevention after stroke of arterial
rigin has been widely studied and prescribed. Cilostazol has been used for
econdary prevention in Asian populations with non-cardioembolic stroke
nd no clinically evident cardiac disease. The purpose of this review was to
etermine the relative effectiveness and safety of cilostazol compared with
spirin in the prevention of stroke and other vascular events in patients with
previous transient ischemic attack (TIA) or ischemic stroke of arterial
rigin.
The authors searched the Cochrane Stroke Group trials register, the
ochrane Central Register of Controlled Trials, and Embase (1980 to May
010) to identify ongoing, unpublished, and published studies relating to
he secondary prevention of vascular events with cilostazol vs aspirin in
atients with stroke of arterial origin. Only randomized controlled trials
omparing cilostazol with aspirin where participants were treated for at least
month and monitored systematically for development of vascular events
defined as stroke, myocardial infarction, or vascular death) were used for the
nalysis. Two independent reviewers selected trials for inclusion, assessed
rial quality, and extracted data. Treatment effect was determined by the
antel-Haenszel method.
The authors identified two trials from China and Japan with 3477
articipants with ischemic stroke of arterial origin. Trials were judged to be
f good quality. Cilostazol, when compared with aspirin, was associated with
significantly lower risk of the composite outcome of vascular events,
ncluding stroke, myocardial infarction, or vascular death (relative risk, 0.72;
5% CI, 0.57-0.91). The proportional benefit of cilostazol over aspirin on
he outcome of any hemorrhagic or ischemic stroke was 33% (95% CI,
4%-48%). Specifically, with respect to hemorrhagic stroke during follow-
p, cilostazol was associated with a risk reduction of 74% (95% CI 45%-87%)
ompared with aspirin. Patients receiving aspirin had more clinically de-
ected bleeding and more extracranial hemorrhage compared with cilostazol
relative risk, 0.74; 95% CI, 0.61-0.90). There were more minor adverse
ffects with cilostazol than aspirin, including headache, gastrointestinal
ntolerance, palpitation, dizziness, tachycardia, angina, and cardiac failure.
Comment: In the Asian population, at least from China and Japan,
ilostazol appears to be superior to aspirin in secondary prevention of
ascular events after a TIA or stroke. The results are even more dramatic in
reventing secondary stroke from intracranial hemorrhage. Cilostazol was
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JOURNAL OF VASCULAR SURGERY
Volume 54, Number 4 Abstracts 1221also associated with fewer major bleeding events than aspirin. One can
conclude that cilostazol is the preferred agent for secondary prevention of
vascular events after stroke of arterial origin in Asian patients who do not
have overt cardiac disease.
Effect of Fibroblast Growth Factor NV1FGF on Amputation and
Death: A Randomized Placebo-Controlled Trial of Gene Therapy in
Critical Limb Ischemia
Belch J, Hiatt WR, Baumgartner I, and the Tamaris Investigators. Lancet
2011;377:1929-37.
Conclusion: Nonviral 1 fibroblast growth factor (NV1FGF) does not
reduce amputation or death in patients with critical limb ischemia.
Summary: Fibroblast growth factor type 1 (FGF1) activates migration,
proliferation, and differentiation of endothelial cells. The result is sprouting
of capillaries in pre-existing vessels. The gene encoding for human FGF1,
when given intramuscularly in the calf or thigh via a naked DNA plasmid,
leads to expression of human FGF1 protein. In an open-label phase 1 trial, a
single intramuscular administration of NV1FGF in patients with critical limb
ischemia improved pain, ulcer size, and hemodynamic variables (Comerota
AJ, et al, J Vasc Surg 2002;35:930-6). The Therapeutic Angiogenesis Leg
Ischemia Study for the Management of Arteriopathy and Non-Healing
Ulcer (TALISMAN) results demonstrated a reduction of 63% in risk of
major amputation and a 56% reduction of the risk of major amputation or
death at 12 months compared with placebo, with no difference in the
primary end point of ulcer healing (Nikol S, Mol Ther 2008;16:672-78).
These two trials provided the stimulus for the phase 3 trial reported here. All
patients had nonhealing ischemic skin lesions and were judged to be such
that revascularization was not possible. There were 525 patients with critical
limb ischemia unsuitable for revascularization. Patients were enrolled from
171 sites in 30 countries. All patients had minor skin gangrene or ischemic
ulcers and met hemodynamic criteria for inclusion. Criteria included ankle
pressure 70 mm Hg, or a toe pressure 50 mm Hg, or both, or a
transcutaneous oxygen pressure 30 mm Hg on the treated leg. Patients
were randomized in a 1:1 ratio to receive NV1FGF at 0.2 mg/mL or
matching placebo. Patients and investigators were blinded to treatment.
Each patient received eight intramuscular injections of their assigned treat-
ment in their index leg on days 1, 15, 29, and 43. Primary end point was time
to major amputation or death at 1 year. Data were analyzed on an intention
to treat basis. There were 266 patients randomized to placebo and 259 to
treatment with NV1FGF. All randomized patients were analyzed. Patients
were a mean age of 70 years (range, 50-92 years), 70% were men, 47% had
a history of coronary artery disease, and 53% had diabetes. The primary end
point or components of the primary end point did not differ between
treatment groups. Major amputation or death occurred in 86 patients in the
placebo group and in 96 patients in the treatment group (HR, 1.11; 95% CI,
0.83-1.49; P  .48). No safety issues were identified with the use of
NV1FGF in the treatment of critical limb ischemia.
Comment: A meta-analysis of trials that included gene-based and cell-
based therapies in peripheral arterial disease concluded such therapies had
potential clinical benefit (De Haro J, et al, Heart Vessels 2009;24:321-8).
However, clinical benefit has not been demonstrated in rigorously controlled
phase 3 trials. One can question the concept of the administration of a single
gene where optimal dosage, routes of administration, duration of administra-
tion, and vectors of administration are all unknown. As currently performed,
gene therapy trials are, unfortunately, still somewhat akin to “shots in the dark.”
One hopes the industry will not abandon the concept of gene therapy for
vascular disease but will seek better preliminary data to optimize dosage, routes
of administration, and vectors of administration of the genetic material.
How do the Type and Location of a Vascular Malformation Influence
Growth in Klippel-Trenaunay Syndrome?
Funayama E, Sasaki S, Oyama A, et al. Plast Reconstruc Surg 2011;127:
340-6.
Conclusion: In Klippel-Trenaunay (KT) syndrome, abnormal subcu-
taneous tissue muscle and bone growth is associated with specific types and
locations of vascular malformations.
Summary: KT syndrome is a mixed vascular malformation with a
combination of capillary nevus, early onset varicosities, and hypertrophy of
tissues and bones of the affected limb. KT has a wide variety of manifesta-
tions. Oduber et al in 2008, proposed a restrictive diagnostic criteria for KT
syndrome (Ann Plast Surg 2008;60:217-223); group A: venous and capil-
lary malformations; group B: abnormal growth of the effected limb. The
authors retrospectively examined 35 patients who satisfied the diagnosis of
KT syndrome by the criteria of Oduber et al. They examined the frequency
of each type of vascular malformation and assessed relationships between
vascular malformations (location and type) and abnormal limb growth (girth
or length). Type and location of vascular malformation and abnormal
circumferential growth were assessed by magnetic resonance imaging (MRI)
and ultrasound imaging. Bone girth was assessed by axial MRI or computed
tomography. Bone length was measured with plain radiographs of the long
s
mones. The authors found no association between vascular malformation
ype with location or leg length. Leg bone circumferential hyperplasia was
bserved in 50% of cases and was related to the presence of intramuscular
omponents of the malformation. A venous malformation in the subcutane-
us tissue was significantly associated with the presence of subcutaneous
ypertrophy. There was a higher frequency of muscle hyperplasia in patients
ith intramuscular lymphatic malformations.
Comment: One difficulty studying vascular malformations is achieving
greement on categorization and description. The criteria of Oduber et al
re useful because they provide a precise description of the patients in the
tudy. The observations that certain patterns of malformation influence
atterns of subcutaneous or muscle hypertrophy may provide a starting
oint for determining what elements of a vascular malformation should be
reated to maximize patient function in the long-term by normalizing
uscle mass or decreasing subcutaneous hypertrophy.
nfectious Complications Following Conversion to Buttonhole Can-
ulation of Native Arteriovenous Fistulas: A Quality Improvement
eport
abriola L, Crott R, Desmet C, et al. Am J Kidney Dis 2011;57:442-8.
Conclusion: Infections events can be decreased with a buttonhole
rocedure of arterial venous access through intensive staff education.
Summary: Buttonhole cannulation of native arteriovenous fistulas
AVFs) with blunt needles was reported in 1977 (Twardowski Z, Contemp
ial Nephrol 1977;18:18-9). The technique has gained in popularity. In the
uttonhole technique, the AVF is repeatedly accessed with blunt needles at
he same site. A tunnel can be created from the skin to the AVF using a
onstant site over six hemodialysis sessions. The tunnel guides the blunt
eedle to the access vessel. Proponents argue the technique makes for easier
annulation, fewer missed sticks, less pain, and faster hemostasis after needle
emoval, with fewer hematomas and aneurysms. Because the buttonhole
echnique requires cannulation through nonhealed skin, it may lead to an
ncreased risk of infectious events associated with AVFs. The authors con-
ucted an observational study to determine whether infections events in-
reased in patients with AVFs switched to buttonhole cannulation. They
scertained infectious events during four periods in their patients with AVFs.
n period 1, the rope-ladder technique for access was used in all patients.
eriod 2 was characterized by a switch to the buttonhole technique. Period
was characterized by use of the buttonhole technique before there were
ducational workshops to minimize infectious complications. Period 4
ncluded the interval after educational workshops on minimizing infectious
omplications. They analyzed 177 patients (mean age, 70.4  11.5 years)
ith 193 AVFs. There were 186,481 AVF days available for analysis. During
his time, 57 infectious events occurred (0.31 events/1000 AVF days).
nfectious events incidents increased after switching to the buttonhole
ethod (0.17 [95% CI, 0.086-0.31], 0.11 [95% CI, 0.0014-0.63], and
.43 [95% CI, 0.29-0.61] event/1000 AVF days in periods 1, 2 and 3,
espectively, P .003). In period 4, infectious events incidents decreased to
.34 events/1000 AVF days. Complicated infectious events (n  12) were
ssentially restricted to period 3 (n  11; 0.153 [95% CI, 0.076-0.273]
vents/1000 AVF days) with a significant decrease in period 4 (n 1; 0.024
95% CI, 0.001-0.118] events/1000 AVF days. The relative risk of a major
nfection in period 3 vs 4 was 6.37 (95% CI, 1.09-138.4, P  .04.)
Comment: Infections of native AVFs are infrequent, but this report did
ocument an increase in infections and complications associated with the
witch to buttonhole cannulations. The authors suspect that technicians
ccessing the fistulas became complacent with the hygiene protocol of the
uttonhole technique. Their suspicion is somewhat supported by a subse-
uent decrease in infectious complications after institution of an educational
rogram emphasizing proper hygiene in accessing of the AVFs with the
uttonhole technique. The data are consistent with the recent emphasis of
eticulous hygiene with access of any type of indwelling intravenous cath-
ter or permanent vascular access device.
eurosonographic Monitoring of 105 Spontaneous Cervical Artery
issections
aracchini C, Tonell S, Meneghetti G, et al. Neurology 2010;75:1864-70.
Conclusions: Changes in the lumen of cervical arteries afflicted with
pontaneous cervical artery dissection occur most frequently within the first
ew months after the dissection, but recanalization may occur up to 1 year
ater. Early recurrence is reasonably common but involves arteries previously
naffected by dissection. Recurrence of spontaneous cervical artery dissec-
ion is strongly associated with a family history of arterial dissection.
Summary: It is generally acknowledged spontaneous cervical artery
issection (sCAD) is a highly dynamic process after the initial event. Infor-
ation on recanalization and recurrence rates in patients with sCAD is
imited, however. Although cervical artery mural hematomas are best de-
ected by cervical magnetic resonance imaging (MRI) with T1 fat suppres-
ion, vascular ultrasound imaging is the test that is most frequently used to
onitor patients with sCAD. In this study, the authors prospectively mon-
